QTc-prolonging drugs and hospitalizations for cardiac arrhythmias

American Journal of Cardiology

Volumn 91, Issue 1, 2003, Pages 59-62

  De Bruin, Marie L ^a,b   Hoes, Arno W ^a,b   Leufkens, Hubert G M ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CISAPRIDE; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DIURETIC AGENT; ERYTHROMYCIN; GLIBENCLAMIDE; HALOFANTRINE; KETANSERIN; MACROLIDE; NEUROLEPTIC AGENT; PENTAMIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QT INTERVAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ANTI-BACTERIAL AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ARRHYTHMIA; CASE-CONTROL STUDIES; FEMALE; GASTROINTESTINAL AGENTS; HISTAMINE H1 ANTAGONISTS; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS;

EID: 0037221410     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02998-3     Document Type: Article

References (30)

1. Haverkamp W., Breithardt G., Camm A.J., Janse M.J., Rosen M.R., Antzelevitch C., Escande D., Franz M., Malik M., Moss A., Shah R. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res. 47:2000;219-233.
2. de Abajo F.J., Rodriguez L.A. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol. 47:1999;307-313.
3. Walker A.M., Szneke P., Weatherby L.B., Dicker L.W., Lanza L.L., Loughlin J.E., Yee C.L., Dreyer N.A. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med. 107:1999;356-362.
4. Wysowski D.K., Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 335:1996;290-291.
5. Bran S., Murray W.A., Hirsch I.B., Palmer J.P. Long QT syndrome during high-dose cisapride. Arch Intern Med. 155:1995;765-768.
6. Glassman A.H., Bigger J.T. Jr. Antipsychotic drugs prolonged QTc interval, Torsades de Pointes, and sudden death. Am J Psychiatry. 158:2001;1774-1782.
7. Burckhardt D., Raeder E., Muller V., Imhof P., Neubauer H. Cardiovascular effects of tricyclic and tetracyclic antidepressants. JAMA. 239:1978;213-216.
8. Zehender M., Meinertz T., Hohnloser S., Geibel A., Hartung J., Seiler K.U., Just H. Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Multicenter Ketanserin Research Group. Clin Physiol Biochem. 8:1990;90-100.
9. van Haarst A.D., van't Klooster G.A., van Gerven J.M., Schoemaker R.C., van Oene J.C., Burggraaf J., Coene M.C., Cohen A.F. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther. 64:1998;542-546.
10. Matson P.A., Luby S.P., Redd S.C., Rolka H.R., Meriwether R.A. Cardiac effects of standard-dose halofantrine therapy. Am J Trop Med Hyg. 54:1996;229-231.
11. Eisenhauer M.D., Eliasson A.H., Taylor A.J., Coyne P.E. Jr, Wortham D.C. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest. 105:1994;389-395.
12. Brandriss M.W., Richardson W.S., Barold S.S. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (Torsades de Pointes) case report and review. Clin Infect Dis. 18:1994;995-998.
13. Lee K.L., Jim M.H., Tang S.C., Tai Y.T. QT prolongation and Torsades de Pointes associated with clarithromycin. Am J Med. 104:1998;395-396.
14. Ball P. Quinolone-induced QT interval prolongation a not-so-unexpected class effect. J Antimicrob Chemother. 45:2000;557-559.
15. Lopez J.A., Harold J.G., Rosenthal M.C., Oseran D.S., Schapira J.N., Peter T. QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol. 59:1987;376-377.
16. Rosati B., Rocchetti M., Zaza A., Wanke E. Sulfonylureas blockade of neural and cardiac HERG channels. FEBS Lett. 440:1998;125-130.
17. Gohn D.C., Simmons T.W. Polymorphic ventricular tachycardia (Torsades de Pointes) associated with the use of probucol. N Engl J Med. 326:1992;1435-1436.
18. Henderson R.A., Lane S., Henry J.A. Life-threatening ventricular arrhythmia (Torsades de Pointes) after haloperidol overdose. Hum Exp Toxicol. 10:1991;59-62.
19. Abernethy D.R., Barbey J.T., Franc J., Brown K.S., Feirrera I., Ford N., Salazar D.E. Loratadine and terfenadine interaction with nefazodone both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther. 69:2001;96-103.
20. Desta Z., Kerbusch T., Flockhart D.A. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther. 65:1999;10-20.
21. Collet J.P., Boivin J.F. Bias and confounding in pharmacoepidemiology. Strom B.L. Pharmacoepidemiology. 2000;765-784 John Wiley Ltd, Chichester.
22. Grobbee D.E., Hoes A.W. Non-potassium-sparing diuretics and risk of sudden cardiac death. J Hypertens. 13:1995;1539-1545.
23. Chin R.L. Laxative-induced hypokalemia. Ann Emerg Med. 32:1998;517-518.
24. Yelamanchi V.P., Molnar J., Ranade V., Somberg J.C. Influence of electrolyte abnormalities on interlead variability of ventricular repolarization times in 12-lead electrocardiography. Am J Ther. 8:2001;117-122.
25. Taylor D.R., Wilkins G.T., Herbison G.P., Flannery E.M. Interaction between corticosteroid and beta-agonist drugs. Biochemical and cardiovascular effects in normal subjects. Chest. 102:1992;519-524.
26. Bouvy M.L., Heerdink E.R., De Bruin M.L., Herings R.M., Leufkens H.G., Hoes A.W. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med. 160:2000;2477-2480.
27. Rosero S.Z., Zareba W., Moss A.J., Robinson J.L., Hajj Ali R.H., Locati E.H., Benhorin J., Andrews M.L. Asthma and the risk of cardiac events in the Long QT syndrome. Long QT Syndrome Investigative Group. Am J Cardiol. 84:1999;1406-1411.
28. Arildsen H., May O., Christiansen E.H., Damsgaard E.M. Increased QT dispersion in patients with insulin-dependent diabetes mellitus. Int J Cardiol. 71:1999;235-242.
29. Yang T., Roden D.M. Extracellular potassium modulation of drug block of IKr. Implications for Torsades de Pointes and reverse use-dependence. Circulation. 93:1996;407-411.
30. Williams C. Baseline rates of disease may account for some arrhythmia risk. Arch Intern Med. 161:2001;1235-1236.